Aquestive Therapeutics, Inc. announced it received a Complete Response Letter from the FDA on January 30, 2026, regarding its drug Anaphylm™ for allergic reactions, citing packaging and administration issues. They plan to resolve these quickly and expect to resubmit by Q3 2026 while also pursuing approvals in Canada and Europe.